Edurant (Rilpivirine Hydrochloride) - Published Studies

Edurant Related Published Studies

Well-designed clinical trials related to Edurant (Rilpivirine)

Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor. [2012]

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. [2012]

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. [2011]

Other research related to Edurant (Rilpivirine)

A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. [2014]

Impact of food and different meal types on the pharmacokinetics of rilpivirine. [2013]

Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response. [2013]

Other possibly related research studies

48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. [2014]